TrialActa pharmacologica Sinica2009

Benefit of standard versus low-dose tirofiban for percutaneous coronary intervention in very elderly patients with high-risk acute coronary syndrome.

Yun-ling Lin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.